cag news page - downloads.hindawi.comdownloads.hindawi.com › journals › cjgh › 2015 › 587109.pdf · The CAG is proud to acknowledge its Benefactor Corporate Sponsors: ...

Can J Gastroenterol Hepatol Vol 29 No 2 March 201564

cag news page

The CAG is proud to acknowledge its Benefactor Corporate Sponsors:

AbbVie Corporation Olympus Canada Inc

Pentax Canada Inc Janssen Inc Takeda Canada Inc

CanadianDigestiveDiseasesWeek

2015

thank you to the over 1000 delegates who made cddW 2015 a great success!CDDW 2015 offered over 90 hours of Section 1 accredited learning and up to 31 credits per delegate (over ¼ of your annual requirement!). Eighty-six sessions over a 3.5 day period included symposia, key lectures, breakfast sessions, small group learning sessions, and paper sessions. Over 150 faculty members, including many international speakers, delivered the program.

help us improve the cddW meeting to cover the topics that are important to you and retrieve your Maincert certificate for cddW!

Follow this link ( http://www.cag-acg.org/ ) to the online CDDW evaluation. We appreciate your feedback and assistance with developing further CAG educational programs.

Stay tuned to the caG ePortal athttp://www.cag-acg.org/cag-education-eportal

If you missed CDDW 2015 or were unable to attend all of the sessions stay tuned to the CAG ePortal. We will be posting CDDW 2015 sessions over the coming months.

caG is pleased to recognize the Major Sponsors and exhibitors of cddW 2015!

PlatinUM GOld Silver brOnZeAbbVie Janssen Inc. PENTAX Medical Merck Canada Inc.

Takeda Canada, Inc. Actavis Specialty Pharmaceuticals Ferring Pharmaceuticals

Olympus Canada Inc. Shire Canada Inc. (IBD)

Gilead Sciences Canada, Inc. Bristol-Myers Squibb Canada

Fairmont Banff Springs

exhibitors

Major Sponsors

Janssen Inc. (Virology)

Procter & Gamble Professional

Hoffman-La Roche Ltd.

Shire Canada Inc. (Rare diseases)

Covidien

Affinity Diagnostics Corp.

Stanton Territorial Health Authority

BioScript Pharmacy

Canadian Agency for Drugs and Technologies in Health

Olympus Canada Inc.

Vantage Endoscopy

MedQuest Medical Inc.

LifeLabs Medical Laboratory

Cook Medical

ALPCO Diagnostics

EndoChoice Inc.

Danone Canada

Pendopharm, a division of Pharmascience

Boston Scientific Ltd.

Abbott Laboratories

KNS Canada Inc.

Medical Futures Inc.

Red Leaf Medical Inc.

NPS Pharma

SuperSonic Imagine

50K

HARVONI™ is indicated for the treatment of chronic hepatitis C virus genotype 1 infection in adults.Refer to the page in the bottom-right icon for additional safety information and for a web link to the product monograph discussing: • Relevant warnings and precautions

regarding combination with other anti-HCV medications, reduced sustained virologic response (SVR) in treatment-experienced patients with certain NS5A mutations, safety and effi cacy in patients who have failed previous therapy with HARVONI, use with potent P-gp inducers, safety and effi cacy in patients with HCV genotype 2-6, use with tenofovir disoproxil fumarate and a pharmacokinetic enhancer, concurrent administration with other medicinal products containing sofosbuvir, safety and effi cacy in patients with decompensated cirrhosis, use in patients with rare hereditary

problems of galactose intolerance, use in patients with severe renal impairment (eGFR <30 mL/min/1.73 m2) or end stage renal disease requiring hemodialysis, use during pregnancy, use while breastfeeding and use in pediatric patients

• Adverse reactions, drug interactions and dosing information

In addition, the page contains the reference list and study parameters relating to this advertisement.* Safety and effi cacy of HARVONI have not been established in patients

with decompensated cirrhosis. ‡ SVR12=sustained virologic response, defi ned as HCV-RNA < lower limit

of quantitation at 12 weeks after the cessation of treatment. § No dosage adjustments are possible for HARVONI. Please consult the

product monograph for complete dosage and administration instructions.

HARVONI™ is a trademark of Gilead Sciences, Inc. or its related companies. © 2015, Gilead Sciences Canada, Inc. All rights reserved.

January 6, 2015 10:35 AM

GGSOFB 16108E IK,ME,LS,CH

S06TC Logos Relinked to Master N/A Page Count for Binding Checked Approved With Correction(s)TC Logos Verifi ed (Language/Tagline) TC Margin for Binding Included Studio

Gilead CMYK TC Specs verifi ed N/A Mock Up Approved ProofreaderHarvoni N/A Images Purchased N/A Separation Checked Art DirectorHarvoni WAVE 2 ad series N/A Images Sized Properly N/A Special Finish Required CopywriterENG 7.875” x 10.5” TC Images Proper Colour Space N/A Working Files in "To Archive" Folder Client Service

7.875” x 10.5”

13s

Marilyn Kehl 7” x 10”

Ilana Korn 0.125

Sarah Higgins 100 %

of treatment-naïve chronic hepatitis C genotype 1 patients (with or without cirrhosis, n=214)* treated for 12 weeks achieved SVR12

(indicative of virologic cure)1†‡

of treatment-naïve chronic hepatitis C genotype 1 patients (with or without cirrhosis, n=214)* treated for 12 weeks achieved SVR12

ONE PILL ONCE A DAY§

NOW AVAILABLE

See additional safety information on page xx.See additional safety information on page xx.

See additional safety information on page xx.See additional safety information on page xx.

GGSOFB 16108E Wave 2 Journal Ad S06.indd 1 1/6/15 10:37 AM

Submit your manuscripts athttp://www.hindawi.com

Stem CellsInternational

Hindawi Publishing Corporationhttp://www.hindawi.com Volume 2014


MEDIATORSINFLAMMATION

of


Behavioural Neurology

EndocrinologyInternational Journal of



Disease Markers


BioMed Research International

OncologyJournal of



Oxidative Medicine and Cellular Longevity


PPAR Research

The Scientific World JournalHindawi Publishing Corporation http://www.hindawi.com Volume 2014

Immunology ResearchHindawi Publishing Corporationhttp://www.hindawi.com Volume 2014

Journal of

ObesityJournal of



Computational and Mathematical Methods in Medicine

OphthalmologyJournal of


Diabetes ResearchJournal of



Research and TreatmentAIDS


Gastroenterology Research and Practice


Parkinson’s Disease

Evidence-Based Complementary and Alternative Medicine

Volume 2014Hindawi Publishing Corporationhttp://www.hindawi.com

cag news page - downloads.hindawi.comdownloads.hindawi.com › journals › cjgh › 2015 › 587109.pdf · The CAG is proud to acknowledge its Benefactor Corporate Sponsors: ...

Documents